NasdaqCM:SLNO

Stock Analysis Report

Executive Summary

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Risks

  • Soleno Therapeutics has significant price volatility in the past 3 months.
  • Soleno Therapeutics is covered by less than 3 analysts.

Share Price & News

How has Soleno Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.0%

NasdaqCM:SLNO

-1.0%

US Biotechs

-1.2%

US Market


1 Year Return

4.0%

NasdaqCM:SLNO

-11.9%

US Biotechs

3.3%

US Market

SLNO outperformed the Biotechs industry which returned -11.9% over the past year.

SLNO matched the United States of America Market (3.3%) over the past year.


Share holder returns

SLNOIndustryMarket
7 Day-7.0%-1.0%-1.2%
30 Day0.7%-3.6%0.8%
90 Day39.0%-0.7%0.9%
1 Year4.0%4.0%-11.1%-11.9%5.6%3.3%
3 Year-42.1%-42.1%9.3%5.4%45.4%35.9%
5 Yearn/a12.5%7.4%59.4%41.7%

Price Volatility Vs. Market

How volatile is Soleno Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Soleno Therapeutics undervalued based on future cash flows and its price relative to the stock market?

3.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Soleno Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Soleno Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Soleno Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Soleno Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Soleno Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Soleno Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Soleno Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

61.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Soleno Therapeutics is high growth as no revenue estimate data is available.

Soleno Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Soleno Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Soleno Therapeutics's earnings growth is expected to exceed the United States of America market average.

Soleno Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Soleno Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Soleno Therapeutics performed over the past 5 years?

-5.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Soleno Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Soleno Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Soleno Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Soleno Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Soleno Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Soleno Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Soleno Therapeutics's financial position?


Financial Position Analysis

Soleno Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Soleno Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Soleno Therapeutics has no debt.

Soleno Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Soleno Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Soleno Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.

Soleno Therapeutics has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -7.9% each year.


Next Steps

Dividend

What is Soleno Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Soleno Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Soleno Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Soleno Therapeutics has not reported any payouts.

Unable to verify if Soleno Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Soleno Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Soleno Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Anish Bhatnagar (49yo)

5.4yrs

Tenure

US$951,911

Compensation

Dr. Anish Bhatnagar, M.D. has been the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 2014, President since December 31, 2013. Dr. Bhatnagar has been Director at Soleno Therapeutics ...


CEO Compensation Analysis

Anish's remuneration is higher than average for companies of similar size in United States of America.

Anish's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.2yrs

Average Tenure

58.5yo

Average Age

The tenure for the Soleno Therapeutics management team is about average.


Board Age and Tenure

5.1yrs

Average Tenure

59yo

Average Age

The tenure for the Soleno Therapeutics board of directors is about average.


Insider Trading

No 3 month individual insider trading information.


Recent Insider Transactions

SellUS$174,90622 May 19
Vivo Capital, LLC
EntityCompany
Shares90,724
Max PriceUS$1.98
BuyUS$159,39218 Mar 19
Oracle Investment Management, Inc.
EntityCompany
Shares130,363
Max PriceUS$1.22
BuyUS$7,470,83527 Dec 18
Abingworth LLP
EntityCompany
Shares4,669,272
Max PriceUS$1.60
BuyUS$027 Dec 18
Abingworth LLP
EntityCompany
Shares4,669,272
Max PriceUS$2.00
BuyUS$4,868,69927 Dec 18
Jack Schuler
EntityIndividual
Shares3,031,002
Max PriceUS$1.61
BuyUS$027 Dec 18
Jack Schuler
EntityIndividual
Shares151,550
Max PriceUS$2.00
BuyUS$2,000,06021 Dec 18
Oracle Investment Management, Inc.
EntityCompany
Shares1,245,135
Max PriceUS$1.61
BuyUS$021 Dec 18
Oracle Investment Management, Inc.
EntityCompany
Shares62,256
Max PriceUS$2.00
SellUS$46,08314 Sep 18
Technology Partners
EntityCompany
Shares22,682
Max PriceUS$2.05

Ownership Breakdown


Management Team

  • Jon Wolter (69yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.8yrs
    • Compensation: $288.00k
  • Anish Bhatnagar (49yo)

    President

    • Tenure: 5.4yrs
    • Compensation: $951.91k
  • David O'Toole (60yo)

    Consultant

    • Tenure: 1.8yrs
    • Compensation: $358.00k
  • Neil Cowen

    Senior Vice President of Drug Development

  • Tony Wondka (57yo)

    Senior Vice President of Research & Development

    • Tenure: 4.5yrs
    • Compensation: $270.00k
  • Patricia Hirano

    Head of Regulatory Affairs and Quality


Board Members

  • Stuart J. Collinson (59yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: $60.91k
  • Thomas Casale

    Member of Advisory Board

  • Ernie Mario (80yo)

    Chairman

    • Tenure: 5.4yrs
    • Compensation: $83.83k
  • Anish Bhatnagar (49yo)

    President

    • Tenure: 5.4yrs
    • Compensation: $951.91k
  • Andrew Sinclair (47yo)

    Director

    • Tenure: 0.6yrs
    • Compensation: $20.23k
  • Glenis Scadding

    Member of Advisory Board

  • Vinny Bhutani

    Member of Advisory Board

  • Robert Christensen

    Member of Advisory Board

  • David Stevenson

    Member of Advisory Board

  • Bill Harris (61yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: $75.94k

Company Information

Soleno Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Soleno Therapeutics, Inc.
  • Ticker: SLNO
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$88.339m
  • Shares outstanding: 31.78m
  • Website: Click here

Number of Employees


Location

  • Soleno Therapeutics, Inc.
  • 1235 Radio Road
  • Suite 110
  • Redwood City
  • California
  • 94065
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SLNONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
6XC1BST (Boerse-Stuttgart)YesCommon StockDEEURNov 2014
6XC1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet tha ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/22 03:20
End of Day Share Price2019/07/19 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.